期刊文献+

不同剂量比索洛尔治疗慢性充血性心力衰竭的疗效及耐受性比较 被引量:4

原文传递
导出
摘要 目的探讨不同剂量比索洛尔对慢性充血性心力衰竭的疗效及耐受性。方法197例慢性充血性心力衰竭(CHF)患者在常规传统治疗基础上口服比索洛尔,按比索洛尔日用总量分为两组,≥10mg/d为高剂量组,共85例,≤5mg/d为低剂量组,共112例,对治疗前、治疗后3个月和6个月做心功能评估及耐受性比较,并做心脏彩色超声心动图,对各项心功能参数进行比较。结果低剂量组开始治疗3个月后LVEF有改善,但总体状况改善不明显,治疗6个月后状况大致同3个月。高剂量组治疗3个月后各项心功能指标均明显改善。高剂量组耐受性略差于低剂量组,差异具有统计学意义(P〈0.05),但均无恶性不良事件发生。结论高剂量组在改善心功能、改善心肌重构方面优于低剂量组,所以只要患者在耐受范围内应尽可能使比索洛尔达到目标剂量。
出处 《中国实用医刊》 2013年第1期90-91,共2页 Chinese Journal of Practical Medicine
  • 相关文献

参考文献4

二级参考文献7

  • 1Hoffman J, Grimm W, Maisch B, et al. Beta blockers in therapy of chronic heart failure. Herz ,2002 ,27 : 150-165.
  • 2Lotze U, Heinke S, Fritzenwanger M, et al. Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts. J Cardiovasc Pharmacol, 2002,39:576-589.
  • 3Osadchii OE, Norton GR, McKechnie R, et al. Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic beta-adrenoreceptor activation. Am J Physiol Heart Circ Physiol, 2007,292 :H1898-H1905.
  • 4Polyakova V,Hein S,Kostin S, et al. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coil Cardiol,2004, 44: 1609- 1618.
  • 5Takenaka H, Kihara Y, Iwanaga Y, et al. Angiotensin Ⅱ, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol,2006,41:989- 997.
  • 6Sicard P, Oudot A, Guilland JC, et al. Dissociation between vascular oxidative stress and cardiovascular function in Wistar Kyoto and spontaneously hypertensive rats. Vascul Pharmacol, 2006,45 : 112-121.
  • 7Consensus recommendations for the management of chronic heart failure.On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure[].The American Journal of Cardiology.1999

共引文献2427

同被引文献28

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部